VALSARTAN LOSARTAN AND IRBESARTAN PRODUCTS LIABILITY LITIGATION

Track this case

Case Number:

1:19-md-02875

Court:

New Jersey

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation

Judge:

Renee Marie Bumb

Firms

Companies

Sectors & Industries:

  1. January 04, 2021

    Special Masters Tapped In Valsartan Contamination MDL

    A New Jersey federal judge on Monday appointed two former federal judges as special masters to oversee settlement negotiations in multidistrict litigation over alleged contamination of the blood pressure drug Valsartan.

  2. December 18, 2020

    No Preemption In Blood Pressure Drug Contamination MDL

    A New Jersey federal judge won't let manufacturers, wholesalers and pharmacies escape multidistrict litigation over their alleged failure to keep contamination out of the blood pressure drug Valsartan, saying federal law doesn't preempt claims by buyers and users of the drug.

  3. September 21, 2020

    Buyers Fight CVS, Walgreens' Bid To Exit Blood Pressure MDL

    A class of consumers urged a New Jersey federal court to reject attempts by Walgreens, CVS and Rite Aid to escape multidistrict litigation alleging they misrepresented a generic high blood pressure drug, saying the pharmacies are shirking obligations by calling themselves drug testers instead of sellers.

  4. July 20, 2020

    CVS, Walgreens Want Out Of Blood Pressure Drug MDL

    Pharmacies including CVS and Walgreens have urged a New Jersey federal judge to drop them from multidistrict litigation alleging they misrepresented a generic high blood pressure drug, arguing that the allegations are barred by federal law and that all liability lies with the manufacturers, not the pharmacies.

  5. February 27, 2020

    Judge Says Attys Didn't 'Get The Message,' Can't Drop Clients

    A New Jersey federal magistrate judge Thursday rejected a second attempt by three attorneys to withdraw as counsel for two clients in multidistrict litigation over a contaminated blood pressure drug, saying they need to explain how they tried to get in contact with their unresponsive clients.

  6. September 24, 2019

    Want Your Rival's Funder Info? Be Specific, Or Don't Bother

    A recent opinion by a New Jersey federal judge in multidistrict litigation over a contaminated blood pressure drug further undercuts the use of speculative arguments about the risks of third-party legal financing and requirements for blanket disclosures, experts said.